中證(zheng)網訊 香雪制藥(300147)7月3日晚(wan)間發(fa)布2018 年(nian)半年(nian)度業績預(yu)告,報(bao)告期內,公司實現歸屬于上(shang)(shang)市公司股東凈利潤約5,101.08萬元~6,072.71萬元,預(yu)計比(bi)上(shang)(shang)年(nian)同期上(shang)(shang)升:5%~25%。
公(gong)(gong)司(si)稱,業(ye)績變動原(yuan)因為:受流感(gan)疫情影(ying)響(xiang),公(gong)(gong)司(si)中(zhong)成藥抗病(bing)毒(du)口(kou)服液業(ye)務較(jiao)去年(nian)同期(qi)有(you)所(suo)(suo)增(zeng)長(chang);橘紅(hong)系列產品的銷量也有(you)所(suo)(suo)增(zeng)長(chang),使(shi)得(de)公(gong)(gong)司(si)經(jing)營結果較(jiao)去年(nian)同期(qi)有(you)所(suo)(suo)增(zeng)長(chang);由于(yu)公(gong)(gong)司(si)發行公(gong)(gong)司(si)債券及新增(zeng)銀行借款,使(shi)得(de)報(bao)告期(qi)內財(cai)務費用增(zeng)長(chang)較(jiao)多;報(bao)告期(qi)內,公(gong)(gong)司(si)獲(huo)得(de)資(zi)產交易賠償款和政府補助,非經(jing)常(chang)性損益對凈利潤的影(ying)響(xiang)金額約(yue)4,500萬元。(董寧寧)